ATE220664T1 - Cyclopentane heptan(ene)säure, 2- heteroarylalkenylderivate als therapeutisches mittel - Google Patents

Cyclopentane heptan(ene)säure, 2- heteroarylalkenylderivate als therapeutisches mittel

Info

Publication number
ATE220664T1
ATE220664T1 AT97907627T AT97907627T ATE220664T1 AT E220664 T1 ATE220664 T1 AT E220664T1 AT 97907627 T AT97907627 T AT 97907627T AT 97907627 T AT97907627 T AT 97907627T AT E220664 T1 ATE220664 T1 AT E220664T1
Authority
AT
Austria
Prior art keywords
derivatives
cyclopentane
acid
compounds
substituted
Prior art date
Application number
AT97907627T
Other languages
German (de)
English (en)
Inventor
Robert M Burk
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Application granted granted Critical
Publication of ATE220664T1 publication Critical patent/ATE220664T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
AT97907627T 1996-02-29 1997-02-20 Cyclopentane heptan(ene)säure, 2- heteroarylalkenylderivate als therapeutisches mittel ATE220664T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/608,794 US5741810A (en) 1996-02-29 1996-02-29 Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
PCT/US1997/002313 WO1997031895A2 (en) 1996-02-29 1997-02-20 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE220664T1 true ATE220664T1 (de) 2002-08-15

Family

ID=24438034

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907627T ATE220664T1 (de) 1996-02-29 1997-02-20 Cyclopentane heptan(ene)säure, 2- heteroarylalkenylderivate als therapeutisches mittel

Country Status (12)

Country Link
US (4) US5741810A (2)
EP (1) EP0888298B1 (2)
JP (1) JP4226650B2 (2)
KR (1) KR19990087352A (2)
CN (1) CN1133434C (2)
AT (1) ATE220664T1 (2)
AU (1) AU725145B2 (2)
BR (1) BR9707892A (2)
CA (1) CA2247208A1 (2)
DE (1) DE69714023T2 (2)
ES (1) ES2178756T3 (2)
WO (1) WO1997031895A2 (2)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU7672096A (en) * 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
IL134840A0 (en) * 1997-09-09 2001-05-20 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
DE69824966T2 (de) * 1997-09-09 2005-04-07 Duke University Aromatische c16-c20-substituierte tetrahydro-prostaglandine verwendbar wie fp agoniste
BR9811779A (pt) * 1997-09-09 2000-09-12 Procter & Gamble Tetrahidro prostaglandina s substituìdas por c16-c20 aromáticos úteis como agonistas fp
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
US6826874B2 (en) * 1999-06-30 2004-12-07 Nippon Steel Corporation Buckling restrained braces and damping steel structures
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6248783B1 (en) * 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
BR0202157A (pt) * 2002-06-07 2005-04-12 Univ Minas Gerais Peptìdeo obtido de veneno escorpião para uso como agente hipotensivo
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7863318B2 (en) * 2005-11-03 2011-01-04 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
KR101437302B1 (ko) 2006-02-07 2014-09-02 가부시키가이샤 아루떼꾸 우에노 프로스타글란딘 유도체의 제조 방법
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN105682645B (zh) 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
WO2016176640A1 (en) * 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
BR112023001073A2 (pt) 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845115A (en) * 1971-05-04 1974-10-29 Upjohn Co 15-lower alkoxy pgf compounds
US3781325A (en) * 1971-05-04 1973-12-25 Upjohn Co 15-methoxy-pgf2a
BE786251A (fr) * 1971-07-14 1973-01-15 Ici Ltd Nouveaux derives du cyclopentane
US4143051A (en) * 1972-07-13 1979-03-06 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US4102894A (en) * 1975-11-19 1978-07-25 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US3974213A (en) * 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
US3980642A (en) * 1972-07-13 1976-09-14 Pfizer Inc. 15-Substitute D-ω-pentanorprostaglandins
US3956284A (en) * 1972-07-13 1976-05-11 Pfizer Inc. Heterocyclic 15-substituted-ω-pentanorprostoglandins
DE2353159A1 (de) * 1972-07-13 1975-03-13 Pfizer Ketophosphonate und verfahren zu deren herstellung
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4036832A (en) * 1974-07-03 1977-07-19 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
IT1053781B (it) * 1974-09-25 1981-10-10 Erba C S P A Ora Farmitalia Omega nor cicloalcil 13.14 deidro prostaglandine
IT1088966B (it) * 1977-11-15 1985-06-10 Erba Carlo Spa 13,14-dideidro-prostaglandine
DE3125271A1 (de) * 1981-06-24 1983-01-13 Schering Ag, 1000 Berlin Und 4619 Bergkamen (delta)(pfeil hoch)8(pfeil hoch),(pfeil hoch)9(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
WO1996036599A1 (en) * 1995-05-18 1996-11-21 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
AU1958597A (en) 1997-09-16
JP4226650B2 (ja) 2009-02-18
US6680337B2 (en) 2004-01-20
CN1218400A (zh) 1999-06-02
US6096902A (en) 2000-08-01
ES2178756T3 (es) 2003-01-01
CA2247208A1 (en) 1997-09-04
WO1997031895A3 (en) 1997-12-18
US20010029304A1 (en) 2001-10-11
AU725145B2 (en) 2000-10-05
HK1017671A1 (en) 1999-11-26
US5741810A (en) 1998-04-21
CN1133434C (zh) 2004-01-07
JP2000506139A (ja) 2000-05-23
DE69714023D1 (en) 2002-08-22
EP0888298A2 (en) 1999-01-07
KR19990087352A (ko) 1999-12-27
BR9707892A (pt) 1999-07-27
US6573390B2 (en) 2003-06-03
US20030191178A1 (en) 2003-10-09
DE69714023T2 (de) 2003-03-13
WO1997031895A2 (en) 1997-09-04
EP0888298B1 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
ATE220664T1 (de) Cyclopentane heptan(ene)säure, 2- heteroarylalkenylderivate als therapeutisches mittel
PT1137409E (pt) Composicoes e metodos para melhoramento da disfuncao sexual feminina humana
DK0660716T3 (da) Ikke-sure 2-cycloalkyl- eller 2-arylkylderivater af cyclopentan-heptansyre som terapeutiske midler
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
CA2242991A1 (en) Use of antioxidant agents to treat cholestatic liver disease
BG103335A (en) Application of fumaric acid derivatives
WO1998022141A3 (en) Enhanced effects for hapten conjugated therapeutics
BR9811099A (pt) Inibidores de urocinase
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
ID26042A (id) Turunan-turunan asam lemak dari asam-asam empedu dan asam empedu
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
EA200100249A1 (ru) 4-аминозамещенные-2-замещенные-1,2,3,4-тетрагидрохинолины в качестве ингибиторов сетр (хэпб)
GT200100008A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2000028999A3 (en) Methods of treating tardive dyskinesia and other movement disorders
BR9811585A (pt) Agonistas de vasopressinas tricìclicas
ES2130268T3 (es) Preparados de acido hialuronico de bajo peso molecular, para estimulacion de formacion de huesos.
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
NO993096L (no) Orale cyklosporinformuleringer
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
MX9603596A (es) Perfluoropolieteres o composiciones de los mismos para prevencion y tratamiento de infecciones virales topicas.
CO5271717A1 (es) Combinaciones farmaceuticas
TR199903271T2 (en) Tokoferol ile karl�la�t�r�lan soluma i�in prolipozom tozlar�.
AU5355498A (en) 15-fluoro prostaglandins as ocular hypotensives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties